An addiction medicine expert with more than 30 IND filings and two FDA successes, Dr. Beyer will help to advance GATC compounds to human clinical trials.
IRVINE, Calif., May 30, 2024 /PRNewswire/ — GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), has engaged GATC advisor Dr. Chad Beyer to oversee FDA Investigative New…









